Biophan CEO Michael Weiner Featured in Extensive Interview with Online Investor News Source ''PR Broadcast''; CEO Presents Company Overview and Discusses Proprietary Medical Device Improvements and Intellectual Property Portfolio
Among the topics covered, Mr. Weiner discusses ways in which Biophan's proprietary technology initiatives provide needed solutions for the biomedical industry. The Company develops cutting-edge technologies to make implanted medical devices such as pacemakers, defibrillators, neurostimulators, stents, and other medical devices safe and/or image compatible with the magnetic resonance imaging (MRI) environment. MRI systems are uniquely powerful diagnostic imaging devices, but they are contraindicated for use with certain common implanted medical devices because of risks that the devices may heat up in the body to dangerous levels or be affected by induced electrical voltages. The FDA has recently issued an advisory to the medical community about these risks with neurostimulators.
Mr. Weiner also discusses Biophan's current development of next-generation, implantable nanotechnology-based batteries that are powered by body heat rather than chemicals, and also an extremely precise, MRI-safe implantable ceramic motor that can be used in a range of applications.
As part of its corporate strategy, Biophan is very aggressive about filing patent protection on the many biomedical innovations that it develops, Mr. Weiner said. The Company has a total of 127 U.S. issued or pending patents, in addition to 46 international issued and pending patents. To listen to the interview, please visit http://prbroadcast.com, and locate the Biophan entry on the home page.
About PR Broadcast
The primary objective of PRBroadcast.com is to provide comprehensive coverage of emerging and well established companies listed on the NASDAQ, AMEX, NYSE and Smallcap exchanges, making the information freely available to our subscribers. The staff and affiliates of PRBroadcast.com consist of seasoned financial and marketing professionals such as securities analysts, news release editors, public relations specialists, and international multimedia personnel dedicated to your company's regional and global exposure. Our experienced staff of professionals can provide the necessary knowledge and expertise that has enabled us to achieve substantial financial success, shareholder liquidity and recognizable benefits for our clients. With offices located in South Florida and New York, we provide direct access to the world's leading capital markets for both startup companies and established, growing organizations. By applying these resources PRBroadcast.com can confidently implement one of many services including enhanced investor awareness and relations, professional consultation, strategic web site development, and private offering announcements. For more information, visit http://prbroadcast.com.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 127 U.S. patents, licenses, or applications. This total includes 37 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 82 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.